Literature DB >> 12850

Atenolol, methyldopa, and chlorthalidone in moderate hypertension.

J Webster, T A Jeffers, D B Galloway, J C Petrie, N P Barker.   

Abstract

Combined treatment with low doses of different drugs is widely used for moderate hypertension. The effects of atenolol and methyldopa at two dose levels and in combination at the lower doses were studied in patients with moderate hypertension on continuous treatment with moderate hypertension on continuous treatment with chlorthalidone. The mean reduction in standing blood pressures obtained with atenolol 150 and 300 mg/day was about 27/17 mm Hg and with methyldopa 750 and 1500 mg/day about 28/14 mm Hg. Combined treatment with atenolol 150 mg/day and methyldopa 750 mg/day for four weeks resulted in a reduction of 38/25 mm Hg. No difference was observed between the two doses of methyldopa. The lower dose of atenolol was better than the lower dose of methyldopa in reducing lying and standing diastolic blood pressures. These findings show that in patients on continuous treatment with chlorthalidone the addition of atenolol alone or methyldopa alone or of atenolol and methyldopa in combination is effective in the treatment of moderate hypertension.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 12850      PMCID: PMC1604043          DOI: 10.1136/bmj.1.6053.76

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  1 in total

1.  Comparison of oxprenolol and methyldopa in hypertension. A within-patient double-blind trial.

Authors:  D W Barritt; A J Marshall; S Heaton
Journal:  Lancet       Date:  1976-03-06       Impact factor: 79.321

  1 in total
  9 in total

Review 1.  Allopathy--the therapeutic legacy.

Authors:  G D Johnston
Journal:  Ir J Med Sci       Date:  1989-01       Impact factor: 1.568

Review 2.  Selecting appropriate antihypertensive drug dosages.

Authors:  G D Johnston
Journal:  Drugs       Date:  1994-04       Impact factor: 9.546

Review 3.  The second Lilly Prize Lecture, University of Newcastle, July 1977. beta-Adrenergic receptor blockade in hypertension, past, present and future.

Authors:  B N Prichard
Journal:  Br J Clin Pharmacol       Date:  1978-05       Impact factor: 4.335

4.  Atenolol and metoprolol in mild hypertension.

Authors:  T A Jeffers; J Webster; B Reid; J C Petrie; N P Barker
Journal:  Br Med J       Date:  1978-11-04

5.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

6.  A study of the effects of atenolol and propranolol on renal function in patients with essential hypertension.

Authors:  R Wilkinson; I M Stevens; M Pickering; V Robson; T Hawkins; D N Kerr; J D Harry
Journal:  Br J Clin Pharmacol       Date:  1980-07       Impact factor: 4.335

Review 7.  Atenolol: a review of its pharmacological properties and therapeutic efficacy in angina pectoris and hypertension.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-06       Impact factor: 9.546

8.  "Third drug" trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta blocker plus thiazide diuretic.

Authors:  D McAreavey; L E Ramsey; L Latham; A D McLaren; A R Lorimer; J L Reid; J I Robertson; M P Robertson; R J Weir
Journal:  Br Med J (Clin Res Ed)       Date:  1984-01-14

9.  Atenolol in the treatment of pregnancy-induced hypertension.

Authors:  K J Thorley; J McAinsh; J M Cruickshank
Journal:  Br J Clin Pharmacol       Date:  1981-11       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.